Scopus Biopharma Stock Revenue
Scopus Biopharma fundamentals help investors to digest information that contributes to Scopus Biopharma's financial success or failures. It also enables traders to predict the movement of Scopus OTC Stock. The fundamental analysis module provides a way to measure Scopus Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Scopus Biopharma otc stock.
Scopus |
Scopus Biopharma OTC Stock Revenue Analysis
Scopus Biopharma's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
CompetitionBased on the latest financial disclosure, Scopus Biopharma reported 0.0 of revenue. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Scopus Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Scopus Biopharma's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Scopus Biopharma could also be used in its relative valuation, which is a method of valuing Scopus Biopharma by comparing valuation metrics of similar companies.Scopus Biopharma is currently under evaluation in revenue category among its peers.
Scopus Fundamentals
Return On Equity | -15.6 | ||||
Return On Asset | -4.61 | ||||
Current Valuation | 1.18 M | ||||
Shares Outstanding | 21.09 M | ||||
Shares Owned By Insiders | 50.66 % | ||||
Shares Owned By Institutions | 2.15 % | ||||
Number Of Shares Shorted | 23.77 K | ||||
Price To Book | 2.42 X | ||||
EBITDA | (26.18 M) | ||||
Net Income | (26.95 M) | ||||
Cash And Equivalents | 1.16 M | ||||
Cash Per Share | 0.05 X | ||||
Total Debt | 2.54 M | ||||
Debt To Equity | 0.61 % | ||||
Current Ratio | 0.31 X | ||||
Book Value Per Share | (0.26) X | ||||
Cash Flow From Operations | (11.42 M) | ||||
Short Ratio | 0.22 X | ||||
Earnings Per Share | (1.51) X | ||||
Target Price | 12.0 | ||||
Beta | 1.16 | ||||
Market Capitalization | 2.17 M | ||||
Total Asset | 8.19 M | ||||
Z Score | -9.9 | ||||
Net Asset | 8.19 M |
Thematic Opportunities
Explore Investment Opportunities
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Scopus OTC Stock
If you are still planning to invest in Scopus Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Scopus Biopharma's history and understand the potential risks before investing.
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data |